Targeting the fetal acetylcholine receptor in rhabdomyosarcoma
Katja Simon-Keller1, Stefan Barth, Angela Vincent
1University Medical Centre Mannheim, University of Heidelberg, Institute of Pathology, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany. katja.simon-keller@medma.uni-heidelberg.de
Introduction:
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Recent efforts to enhance overall survival of patients with clinically advanced RMS have failed and there is a demand for conceptually novel treatments. Immune therapeutic options targeting the fetal nicotinic acetylcholine receptor (fnAChR), which is broadly expressed on RMS, are novel approaches to overcome the therapeutic resistance of RMS. Expression of the fnAChR is restricted to developing fetal muscles, some apparently dispensable ocular muscle fibers and thymic myoid cells. Therefore, after-birth fnAChR is a tumor-associated and almost tumor-specific antigen on RMS cells.
Areas Covered:
This review gives an overview on nAChR function and expression pattern in RMS tumor cells, and deals with the immunological significance of fnAChR-expressing cells, including the risk of anti-nAChR autoimmunity as a potential side effect of fnAChR-directed immunotherapies. The article also addresses the advantages and disadvantages of vaccination strategies, immunotoxins and chimeric T cells targeting the fnAChR.
Expert Opinion:
Finally, we suggest technical and biological strategies to improve the available immunotherapeutic tools including increasing the in vivo expression of the target fnAChR on RMS cells.
Insights
Rhabdomyosarcoma (RMS) is a childhood cancer. Targeting the fetal nicotinic acetylcholine receptor (fnAChR) on RMS cells offers a novel immunotherapy approach to overcome treatment resistance.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma.
- Current treatments for advanced RMS have limited efficacy, necessitating novel therapeutic strategies.
- The fetal nicotinic acetylcholine receptor (fnAChR) is a tumor-associated antigen expressed on RMS cells.
Purpose of the Study:
- To review the role of fnAChR in RMS.
- To discuss the potential of fnAChR-targeted immunotherapies for RMS treatment.
- To explore strategies for improving fnAChR-based immunotherapeutic efficacy.
Main Methods:
- Review of existing literature on fnAChR expression and function in RMS.
- Analysis of immunological significance of fnAChR-expressing cells.
- Evaluation of different immunotherapy modalities targeting fnAChR.
Main Results:
- fnAChR is broadly expressed on RMS cells, making it a promising therapeutic target.
- Immunotherapies targeting fnAChR, including vaccination, immunotoxins, and chimeric T cells, are discussed.
- Potential risks such as anti-nAChR autoimmunity are considered.
Conclusions:
- fnAChR-targeted immunotherapies represent a novel approach for RMS treatment.
- Strategies to enhance in vivo fnAChR expression on RMS cells are proposed.
- Further research is needed to optimize these immunotherapeutic tools and mitigate side effects.
